Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies

导出原文传递

翻译打印收藏纠错

作者： Attwood, S. E. ^[1] ; Ell, C. ^[2] ; Galmiche, J. P. ^[3] ; Fiocca, R. ^[4] ; Hatlebakk, J. G. ^[5] ; Hasselgren, B. ^[6] ; Langstrom, G. ^[7] ; Jahreskog, M. ; Eklund, S. ; Lind, T. ; Lundell, L.

作者单位： AstraZeneca R&D, Molndal, Sweden ^[1] Univ Genoa, Genoa, Italy ^[2] Sana Klinikum Offenbach, Frankfurt, Germany ^[3] Haukeland Hosp, N-5021 Bergen, Norway ^[4] Karolinska Univ Hosp, Karolinska Inst, Ctr Digest Dis, Dept Surg,CLINTEC, Stockholm, Sweden ^[5] CHU Nantes, Hotel Dieu, F-44035 Nantes 01, France ^[6] North Tyneside Gen Hosp, North Shields, Tyne & Wear, England ^[7]

发布时间 2015-07-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Alimentary Pharmacology and Therapeutics

2015年41卷11期

1162-1174页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies

Alimentary Pharmacology and Therapeutics

相似文献

Alimentary Pharmacology and Therapeutics

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies

Alimentary Pharmacology and Therapeutics

相似文献

Alimentary Pharmacology and Therapeutics

相关期刊

检索历史清除